Age at diagnosis, diabetes duration and the risk of cardiovascular disease in patients with diabetes mellitus: a cross-sectional study.

Xuelin Yao, Jie Zhang, Xiaoqian Zhang, Tian Jiang, Yi Zhang, Fang Dai, Honglin Hu, Qiu Zhang
Author Information
  1. Xuelin Yao: Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  2. Jie Zhang: Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  3. Xiaoqian Zhang: Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  4. Tian Jiang: Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  5. Yi Zhang: Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  6. Fang Dai: Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  7. Honglin Hu: Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  8. Qiu Zhang: Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei, China.

Abstract

Background: The purpose of the study was to evaluate characteristics and risk of cardiovascular disease (CVD) according to age at diagnosis and disease duration among adults with diabetes mellitus (DM).
Methods: The association between age at diagnosis, diabetes duration and CVD were examined in 1,765 patients with DM. High risk of estimated ten-year atherosclerotic cardiovascular disease (ASCVD) was performed by the Prediction for ASCVD Risk in China (China-PAR) project. Data were compared with analysis of variance and χ2 test, respectively. Multiple logistic regression was used to determine the risk factors of CVD.
Results: The mean age at diagnosis (± standard deviation) was 52.91 ± 10.25 years and diabetes duration was 8.06 ± 5.66 years. Subjects were divided into early-onset DM group (≤43 years), late-onset DM group (44 to 59 years), elderly-onset DM group (≥60 years) according to age at diagnosis. diabetes duration was classified by 5 years. Both early-onset and longest diabetes duration (>15 years) had prominent hyperglycaemia. diabetes duration was associated with the risk of ischemic stroke (odds ratio (OR), 1.091) and coronary artery disease (OR, 1.080). Early-onset group (OR, 2.323), and late-onset group (OR, 5.199), and hypertension (OR, 2.729) were associated with the risk of ischemic stroke. Late-onset group (OR, 5.001), disease duration (OR, 1.080), and hypertension (OR, 2.015) and hyperlipidemia (OR, 1.527) might increase the risk of coronary artery disease. Aged over 65 (OR, 10.192), central obesity (OR, 1.992), hypertension (OR, 18.816), cardiovascular drugs (OR, 5.184), antihypertensive drugs (OR, 2.780), and participants with disease duration >15 years (OR, 1.976) were associated with the high risk of estimated ten-year ASCVD in participants with DM.
Conclusion: Age at diagnosis, diabetes duration, hypertension and hyperlipidemia were independent risks of CVD. Longest (>15 years) diabetes duration increased the high risk of ten-year ASCVD prediction among Chinese patients with DM. It's urgent to emphasize the importance of age at diagnosis and diabetes duration to improve primary complication of diabetes.

Keywords

References

  1. Curr Med Res Opin. 2005 Jul;21(7):989-98 [PMID: 16004665]
  2. Lancet Diabetes Endocrinol. 2014 Dec;2(12):935-43 [PMID: 25081582]
  3. Diabetes. 2023 Jan 1;72(1):19-32 [PMID: 36256836]
  4. Diabetologia. 2020 Nov;63(11):2305-2314 [PMID: 32820349]
  5. Hypertension. 2018 Jun;71(6):e13-e115 [PMID: 29133356]
  6. Diabetes Care. 2016 Jan;39(1):101-9 [PMID: 26577418]
  7. Diabetes Res Clin Pract. 2022 Aug;190:110022 [PMID: 35905888]
  8. Circ Res. 2020 Feb 14;126(4):439-452 [PMID: 31852393]
  9. Lancet. 2010 Jun 26;375(9733):2215-22 [PMID: 20609967]
  10. Diabetes Res Clin Pract. 2022 Jun;188:109899 [PMID: 35525499]
  11. J Paediatr Child Health. 2014 Nov;50(11):874-9 [PMID: 24893825]
  12. Lancet Diabetes Endocrinol. 2020 Apr;8(4):325-336 [PMID: 32135131]
  13. Cardiovasc Diabetol. 2020 Apr 3;19(1):45 [PMID: 32245386]
  14. Obesity (Silver Spring). 2019 Nov;27(11):1898-1905 [PMID: 31549787]
  15. Rev Invest Clin. 2011 Mar-Apr;63(2):198-209 [PMID: 21714438]
  16. Diabetologia. 2022 Jan;65(1):3-13 [PMID: 34837505]
  17. Diabetes Care. 2014;37(1):24-30 [PMID: 24356594]
  18. Lancet. 2020 Mar 7;395(10226):795-808 [PMID: 31492503]
  19. Bull World Health Organ. 2016 Jan 1;94(1):46-57 [PMID: 26769996]
  20. Biomed Environ Sci. 2022 Jul 20;35(7):633-640 [PMID: 35945178]
  21. J Clin Sleep Med. 2018 Jan 15;14(1):109-117 [PMID: 29198294]
  22. Lancet Diabetes Endocrinol. 2016 Feb;4(2):115-24 [PMID: 26704379]
  23. J Diabetes Investig. 2022 Jun;13(6):1062-1072 [PMID: 35119212]
  24. Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Feb 6;52(2):165-169 [PMID: 29429271]
  25. BMJ. 2020 Apr 28;369:m997 [PMID: 32345662]
  26. Zhonghua Nei Ke Za Zhi. 2020 Jan 1;59(1):18-22 [PMID: 31887831]
  27. Acta Pharmacol Sin. 2019 Jan;40(1):1-8 [PMID: 29867137]
  28. N Engl J Med. 2015 Oct 29;373(18):1720-32 [PMID: 26510021]
  29. Circulation. 2016 Nov 8;134(19):1430-1440 [PMID: 27682885]
  30. J Diabetes. 2020 Feb;12(2):102-104 [PMID: 31411812]
  31. Chronic Dis Transl Med. 2016 Oct 21;2(2):102-109 [PMID: 29063030]
  32. Diabetologia. 2021 Apr;64(4):814-825 [PMID: 33452586]
  33. Diabetologia. 2014 Dec;57(12):2465-74 [PMID: 25226881]
  34. Lancet. 2021 Jul 3;398(10294):5-7 [PMID: 34217400]
  35. Diabetes. 2022 Feb 1;71(2):184-205 [PMID: 34732537]
  36. Cardiovasc Diabetol. 2017 Sep 15;16(1):114 [PMID: 28915818]
  37. Diabetologia. 2021 Feb;64(2):275-287 [PMID: 33313987]
  38. Curr Pharm Des. 2013;19(32):5695-703 [PMID: 23448484]
  39. Curr Med Sci. 2019 Oct;39(5):754-758 [PMID: 31612393]
  40. Diabetes Res Clin Pract. 2022 Jan;183:109119 [PMID: 34879977]
  41. Cardiovasc Diabetol. 2018 Aug 31;17(1):122 [PMID: 30170598]
  42. BMJ. 2012 Jun 07;344:e3564 [PMID: 22677795]
  43. Diabetes Obes Metab. 2021 Jun;23(6):1361-1370 [PMID: 33620747]
  44. BMJ. 2019 Dec 30;367:l6720 [PMID: 31888885]
  45. Lipids Health Dis. 2018 May 8;17(1):102 [PMID: 29739462]
  46. Nat Rev Nephrol. 2019 Jun;15(6):327-345 [PMID: 30894700]
  47. Curr Diab Rep. 2014 Jan;14(1):453 [PMID: 24292971]
  48. Int J Cardiol. 2019 Mar 1;278:280-284 [PMID: 30291010]
  49. Diabetes Care. 2018 Apr;41(4):731-738 [PMID: 29317451]

MeSH Term

Adult
Aged
Humans
Cardiovascular Diseases
Cross-Sectional Studies
Coronary Artery Disease
Hypertension
Atherosclerosis
Ischemic Stroke
Diabetes Mellitus

Word Cloud

Created with Highcharts 10.0.0ORdurationdiabetesriskdiseaseyearsdiagnosisDM1agegroupcardiovascular5CVDASCVD2hypertensionpatientsten-year±>15associatedstudyaccordingamongmellitusestimated10early-onsetlate-onsetDiabetesischemicstrokecoronaryartery080hyperlipidemiadrugsparticipantshighAgeBackground:purposeevaluatecharacteristicsadultsMethods:associationexamined765HighatheroscleroticperformedPredictionRiskChinaChina-PARprojectDatacomparedanalysisvarianceχ2testrespectivelyMultiplelogisticregressionuseddeterminefactorsResults:meanstandarddeviation52912580666Subjectsdivided≤434459elderly-onset≥60classifiedlongestprominenthyperglycaemiaoddsratio091Early-onset323199729Late-onset001015527mightincreaseAged65192centralobesity99218816184antihypertensive780976Conclusion:independentrisksLongestincreasedpredictionChineseurgentemphasizeimportanceimproveprimarycomplicationmellitus:cross-sectionalmacrovascularcomplications

Similar Articles

Cited By (6)